Many continuous variables should be analyzed using the relative scale: a case study of β2-agonists for preventing exercise-induced bronchoconstriction

Harri Hemilä and Jan O. Friedrich

Supplementary File 1

This is supplementary material to a paper by Hemilä and Friedrich (2019)

Published in Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/

2019-8-7

Harri Hemilä
Department of Public Health,
University of Helsinki,
Helsinki, FIN-00014 Finland
harri.hemila@helsinki.fi
http://www.mv.helsinki.fi/home/hemila

Contents

|                          | Page |
|--------------------------|------|
| Explanations and Abbreviations: | 2    |
| Table S1: Extraction of IPD data of the 14 studies | 3    |
| Measurements of IPD findings of two studies from figures | 4    |
| Table S2: Extraction of the study means data | 6    |
| Table S3: Calculation of the absolute and relative effects for Fig. 5 | 10   |
| Data extraction inconsistencies and errors in Bonini et al. (2013) | 11   |
| Table S4: Data extraction inconsistencies and errors in Bonini et al. (2013) | 12   |
| Printouts of statistical calculations | 16   |
Explanations and Abbreviations:

Albuterol: a synonym in the USA for salbutamol

FEV₁: forced expiratory volume in 1 second (the volume a person is able to exhale in 1 s)

IPD: individual participant data

MDI: metered dose inhaler

“1 hour test” indicates exercise test carried out 1 hour after the drug administration

“Pre-drug as baseline” indicates that exercise-induced FEV₁ decline is calculated from the FEV₁ level before drug administration

“Post-drug as baseline” indicates that exercise-induced FEV₁ decline is calculated from the FEV₁ level after drug administration
Extraction of IPD data of the 14 studies

The methods of 12 IPD studies were described by Bonini et al. (2013). The methods of the two studies listed below were not described by Bonini et al.

Robertson (1994): 8 nonsmoking asthmatic men. They were all taking β2-agonists and regular inhaled corticosteroids. Inhaled corticosteroids were continued during the study. Double-blinded, cross-over study.

Schoeffel (1981): 10 participants (3 male, 7 female) with asthma. They were all taking β2-agonists and some used inhaled corticosteroids. Single-blind randomized study.

Table S1: Extraction of IPD data of the 14 studies

| Study             | Dose of β2-agonist; IPD extracted from; time of exercise test after the drug                                                                 |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Anderson (2001)   | Salbutamol 200 μg Table 2 (p. 896): 30 min test The mean of Diskus and pMDI was calculated as the outcome                                       |
| Boner (1994)      | Salbutamol 200 μg Table 3 (p. 937): 3 hour test                                                                                           |
| de Benedictis (1996) | Salmeterol 50 μg Table 2 (p. 2101): 1 hour test                                                                                           |
| de Benedictis (1998) | Salbutamol 200 μg Table 2 (p. 354): 20 min test                                                                                          |
| Debelic (1988)    | Reproterol 1 mg Table 1 (p. 27): 15 min test                                                                                              |
| Dinh Xuan (1989)  | Terbutaline 500 μg Fig 1 (p. 509): 15 min test Max percent decrease in FEV1 within 60 min measured from Fig 1, see p. 3                   |
| Green (1992)      | Salmeterol 50 μg Table 1 (p. 1015): 1 hour test; Table 2 (p. 1016): Pre-drug – Post-drug changes                                           |
| Henriksen (1983)  | Terbutaline 32.5 μg Table 1, Before budesonide administration (p. 995): 15 min test The FEV1 decline is calculated as absolute decline (Δ) from B-2 (Baseline-2) |
| Henriksen (1992)  | Salbutamol 200 μg Table III (p. 1179): 30 min test (Test 1) Pre-drug – Post-drug changes                                                    |
| Pearlman (2007)   | Salbutamol (levalbuterol 90 μg) Table 2 (p. 732): 30 min test Pre-drug as baseline                                                        |
| Robertson (1994)  | Salbutamol 200 μg Table 1 (p. 1980): 30 min test; calculated as Pre-drug – Post-exercise difference                                    |
| Simons (1997)     | Salmeterol 50 μg Fig 2A, Day 1 morning (p. 658): 1 hour test Results were measured from the figure, see p. 4 of this Supplement         |
| Walker (1986)     | Bitolterol 1.0 mg Table I (p. 34): 45 min test; calculated as Pre-drug – Post-exercise difference                                        |
Measurements of IPD findings of two studies from figures

Measurement of Dinh Xuan (1989) results from Fig 1

Dinh Xuan reported the effect of terbutaline on post-exercise FEV$_1$ decline for 10 participants in a figure, see below. The lowest FEV$_1$ value after exercise was measured with a graphics program and the maximal FEV$_1$ decline was calculated. See Supplementary file 2 for the measurements and calculations.
Measurement of Simons (1997) results from Fig 2A

Simons reported the FEV\textsubscript{1} levels (as % predicted) before treatment, and after treatment and exercise. Data for the same 14 participants are reported for both placebo (left) and salmeterol (right) tests, see the figure below. However, the lines overlap to such an extent that only 11 participants could be clearly identified for both the placebo and salmeterol tests. The 11 participants are indicated by the red lines and numbered from 1 to 11. See Supplementary file 2 for the measurement and calculation of the FEV\textsubscript{1} changes in these 11 participants. Comparison of the mean and SD values we measured from the published figures and Simons report indicates close similarity in the means, see below. Thus, we were able to capture most of the findings.

| N: | Simons Table 2 | Our calculation |
|----|----------------|-----------------|
|    | published      | Supplementary file 2 |

| Exercise-induced FEV\textsubscript{1} decline (%) mean±SD: |
|-------------------------------------------------------------|
| Salmeterol
| Maximum fall | -7±6 | -7.9±5.2 |
| Placebo
| Maximum fall | 24±12 | 23.6±11.4 |

![Graph showing FEV1 levels before and after treatment and exercise](image)
Extraction of the study means data

The following Table S2 describes the specific time points and the comparisons, from which we extracted the FEV\textsubscript{1} changes in the placebo and β\textsubscript{2}-agonist tests. The studies with IPD are listed to make this list consistent with Bonini’s Analysis 1.1. but the IPD estimates are not added to this table, see Table S1. Two parallel-group studies (Kemp 1994 and Vazquez 1984) are not included in our analysis.

For the references to the studies and to a description of the studies, see Bonini [11]:
https://doi.org/10.1002/14651858.CD003564.pub3
https://www.ncbi.nlm.nih.gov/pubmed/24089311

The number of participants in the cross-over studies is indicated by N.

**Table S2. Extraction of the study means data**

| Study            | Dose of β\textsubscript{2}-agonist; IPD extracted from; time of exercise test after the drug | N  | FEV\textsubscript{1} change |
|------------------|-------------------------------------------------------------------------------------------------|----|-----------------------------|
| Anderson (2001)  | IPD                                                                                             | 27 |                             |
| Blake (1999)     | Albuterol 180 μg Table 3: 1 hour test Pre-drug as the baseline                                  | 24 | +9.7%                       |
|                   |                                                                                                  |    | -11.4%                      |
| Boner (1994)     | IPD                                                                                             | 15 |                             |
| Bronsky (1995)   | Albuterol powder 200 μg Table 1: 15 min test                                                    | 44 | -6%                         |
|                   |                                                                                                  |    | -23%                        |
| Bronsky (1999)   | Salmeterol Diskus 50 μg Fig 1 and text: 1 hour test                                             | 24 | -1.4%                       |
| Bronsky (2002)   | Albuterol 180 μg Fig 1: 15 min test                                                            | 17 | -1.4%                       |
|                   |                                                                                                  |    | -37.1%                      |
| Carlsen (1995)   | Salmeterol 50 μg Table 2: 10-12 hour test                                                      | 23 | -18%                        |
|                   |                                                                                                  |    | -30%                        |
| Cavagni (1993)   | Salbutamol MDI 200 μg Table 4: 10 min test                                                     | 9  | -15.92%                     |
|                   |                                                                                                  |    | -28.93%                     |
| Clarke (1990)    | Fenoterol 100 μg Table 1, Day 2: 10 min test                                                   | 20 | +19.9%                      |
|                   |                                                                                                  |    | -9.8%                       |
| Daughbjerg (1996)| Salbutamol 400 μg Page 685 bottom: 3 hour test, the “median” is reported, but we analyze it as an approximation to the mean. | 15 | -17%                        |
| Debelic (1988)   | IPD                                                                                             | 16 |                             |
| De Benedictis (1996) | IPD                                                                                   | 12 |                             |
| De Benedictis (1998) | IPD                                                                                   | 12 |                             |
| Del Col (1993)   | Albuterol MDI 200 μg Table 3: 10 min test                                                      | 15 | -2.37%                      |
| Dinh Xuan (1989) | IPD                                                                                             | 10 |                             |
| Study                    | Dose of $\beta_2$-agonist; IPD extracted from; time of exercise test after the drug | N | FEV$_1$ change $\beta_2$-Agonist | FEV$_1$ change Placebo |
|--------------------------|----------------------------------------------------------------------------------|--|----------------------------------|------------------------|
| Egglestone (1981)        | Terbutaline 500 μg Table I: 1 hour test                                         | 17 | -1.9%                           | -31%                   |
|                          | Comparison to the Pre-drug level Calculations of the FEV$_1$ declines are as follows: Terbutaline: FEV$_1$ change of 0.37 L is 10% of the Pre-drug level, thus Pre-drug level is 3.7 L. Pre-drug to Post-drug is +0.37 L and Post-drug to Post-exercise is -0.44 L; thus, Pre-drug to Post-exercise is -0.07 L. Thus FEV$_1$ decline is -1.9% (= -0.07 L/3.7 L). Placebo: Pre-exercise FEV$_1$ level is 3.56 L (=1.14 /0.32). Pre-drug is 3.56 L – 0.05 L = 3.51 L. Thus, FEV$_1$ decline: (-1.14 + 0.05)/3.51 = 31% | |
| Ferrari (2000)           | Formoterol 12 μg Page 511 middle: 15 min test                                   | 14 | -5.9%                           | -29.3%                 |
| Green (1992)             | IPD                                                                             | 13 |                                  |                        |
| Grönneröd (2000)         | Formoterol 9 μg Table 2: 15 min test                                           | 27 | -2.5%                           | -18.4%                |
| Hawksworth (2002)        | Ventolin HFA 180 μg Fig 1 and p. 475 left: 30 min test                          | 24 | -15.4%                          | -33.7%                |
| Henriksen (1983)         | IPD                                                                             | 14 |                                  |                        |
| Henriksen (1992)         | IPD                                                                             | 12 |                                  |                        |
| Hills (1976)             | Salbutamol: 200 μg Fig 2: 20 min test                                           | 19 | +4.8%                           | -35.9%                |
| König (1981)             | Metaproterenol inhaler 1.3 mg Table 3: 1 hour test (Study 2) Pre-drug as the baseline level. Calculations of the FEV$_1$ declines are as follows: Metaproterenol: FEV$_1$ was increased by 20% by metaproterenol (i.e. Post-drug level is 120%). Post-drug to Post-exercise decline is 19% of the 120%. Thus FEV1 decline is -15.8% (= -19%/120%) from Pre-drug level. Placebo: FEV$_1$ was increased by 6% by placebo (i.e. Post-drug level is 106%). Post-drug to Post-exercise decline is 36% of the 106%. Thus FEV1 decline is -34% (= -36%/106%) from the Pre-drug level. | 24 | -15.8%                          | -34%                   |
| Study                  | Dose of β2-agonist; time of exercise test after the drug | FEV<sub>1</sub> change | β<sub>2</sub>-Agonist | Placebo |
|-----------------------|---------------------------------------------------------|-------------------------|------------------------|---------|
| König (1984)          | Fenoterol 0.8 mg Table 2: 10 min test (Run 1)           | 12                      | -2.5%                  | -27.8%  |
| Larsson (1982)        | Fenoterol 400 μg Fig 1: 10 min test Pre-drug as baseline | 8                       | +22.6%                 | -15.7%  |
| McAlpine (1990)       | Salbutamol 200 μg Table 1: 2 hour test Comparison Pre-drug vs. 2 hour test Calculations of the FEV<sub>1</sub> declines are as follows: Salbutamol: FEV<sub>1</sub> was increased by 10.0% by salbutamol (i.e. Post-drug level is 110% = 3.39 L/3.08 L). Post-drug to Post-exercise decline is 14.1% of the 110%. Thus FEV<sub>1</sub> decline is -12.8% (= -14.1%/110%) from the Pre-drug level. Placebo: FEV<sub>1</sub> was not changed by placebo. Post-drug to Post-exercise decline is 32.7%, which is thus also Pre-drug to Post-exercise change. | 12 | -12.8% | -32.7% |
| McFadden (1986a)      | Albuterol 200 μg Table II: 15 min test Comparison Pre-drug vs. 10 min Calculations of the FEV1 declines are as follows: Albuterol: 3.58/3.23 = 1.108 → +10.8% Placebo: 2.95/3.25 = 0.908 → -9.2% | 15 | +10.8% | -9.2% |
| McFadden (1986b)      | Albuterol 180 μg Table II: 15 min test Comparison Pre-drug vs. 5 min Calculations of the FEV<sub>1</sub> declines are as follows: Albuterol: 3.69/3.13 = 1.179 → +17.9% Placebo: 2.67/3.14 = 0.850 → -15.0% | 20 | +17.9% | -15.0% |
| Morton (1989)         | Rimiterol 400 μg Fig 1 and p. 64 left top: 2 min test    | 10                      | +2.807%                | -24.54% |
| Newnham (1993)        | Salbutamol 200 μg                                       | 11                       | -3.8%                  | -27.1%  |
| Study                  | Dose of β2-agonist; IPD extracted from; time of exercise test after the drug | N a) | β2-Agonist FEV₁ change | Placebo FEV₁ change |
|-----------------------|--------------------------------------------------------------------------------|------|------------------------|---------------------|
| Fig 1 and p. 441: 1 hour test | Pre-drug as the baseline Calculations of the FEV₁ declines are as follows: Salbutamol: FEV₁ was increased by 5.2% by salbutamol (i.e. Post-drug level is 105.2% = 3.41 L/ 3.24 L). Post-drug to Post-exercise decline is 4.0% of the 105.2%. Thus FEV₁ decline is -3.8% (= -4.0%/105.2%) from the Pre-drug level. Placebo: FEV₁ was not changed by placebo. Post-drug to Post-exercise decline is -27.1%, which is also Pre-drug to Post-exercise change. | 9    | -5.6%                  | -27.5%              |
| Patessio (1991)       | Salbutamol 200 μg Fig 2: 20 min test | 12   | -8.2%                  | -24.8%              |
| Pearlman (2006)       | Albuterol 180 μg Table 3: 15 min test | 21   | -3.52%                 | -11.11%             |
| Pearlman (2007)       | IPD Table 3: 15 min test | 15   | -10.2%                 | -21.8%              |
| Philip (2007)         | Salmeterol 50 μg Table 2: 2 hour test | 46   | -7.6%                  | -22.4%              |
| Richter (2002)        | Salmeterol 50 μg Table 3: 30 min test | 25   | -10.0%                 | -31.1%              |
| Shapiro (2002)        | Albuterol 180 μg Table II: 15 min test | 17   | -11.8%                 | -31.9%              |
| Sturani (1983)        | Salbutamol 200 μg Fig 1B: 30 min test Pre-drug as baseline | 12   | -4.1%                  | -14.4%              |
| VanHalstma (2010)     | Albuterol 180 μg Fig 1, Caffeine 0 mg/kg: 15 min test | 10   | -16%                   | -33.9%              |
| Walker (1986)         | IPD                                    | 12   | -16%                   | -33.9%              |
| Wolley (1990)         | Terbutaline 500 μg Fig 2: 15 min test Pre-drug as baseline | 12   | -16%                   | -33.9%              |
Table S3: Calculation of the absolute and relative effects for Fig. 5: the Anderson (2001) trial as an example

| A: Absolute effect of β₂-agonists |  |  |  |  |
| --- | --- | --- | --- | --- |
| Placebo | β₂-Agonist | Effect | 95% CI |
| Mean | Mean | Absolute difference | SE | |
| -39.4% | -11.0% | 28.4 pp | 3.0 pp | 22.5 - 34.3 pp |

| B: Relative effect of β₂-agonists: Transformation to the relative scale by dividing by placebo test FEV₁ decline |  |  |  |  |
| --- | --- | --- | --- | --- |
| Placebo | β₂-Agonist | Effect | 95% CI |
| Mean | Mean | Relative difference | SE | |
| -1.0 | -0.28 | 0.72 | 0.076 | 0.57 - 0.87 |

| C: Relative effect of β₂-agonists from the slope of linear regression |  |  |  |  |
| --- | --- | --- | --- | --- |
| Effect | 95% CI |
| Slope | SE | |
| 0.71 | 0.048 | 0.62 - 0.80 |

This table demonstrates the calculation of the 95% CIs for the three forest plots of Fig. 5. The results shown are for the Anderson (2001) trial.

A: The absolute effect of β₂-agonists is calculated as the difference in the effects on the placebo and β₂-agonist tests, and the SE for the difference is calculated from the individual paired differences of the cross-over trial.

B: The relative effect is calculated by the transformation to the relative scale by dividing by the placebo test FEV₁ decline. Thus, on this scale, the effect of β₂-agonist is 72% reduction in the FEV₁ decline (based on 0.72 = 28.4/39.4), and the SE for that relative effect estimate is 7.6 pp (based on 0.076 = 3.0/39.4).

C: As a second method, the relative effect was calculated by linear regression, forcing the line though the origin, similar to Fig. 2 in the report, but restricting to the Anderson (2001) trial. The slope of 0.71 has SE 0.048, corresponding to 71% effect with SE of 4.8 pp, see Additional File 1 for the calculation.

In each of the three scales, the 95% CI was calculated as the effect ± 1.96×SE. Therefore, each confidence interval is symmetric on the scale shown in Fig. 5.
Data extraction inconsistencies and errors in Bonini et al. (2013)

Our study did not intend to reproduce Bonini’s main meta-analysis which was labeled Analysis 1.1 in their paper [11]. There are some errors and inaccuracies in the data extraction by Bonini and therefore exact reproduction of their Analysis 1.1 is not possible or relevant. Table S4 below describes the differences between Bonini’s data extraction and ours.

Some of the errors are particularly large. In the Bronsky (1995) and the Del Col (1993) trials, Bonini added 10 and 20 percentage points to the published FEV₁ declines in the β₂-agonist tests, see below.

In particular, given that the effect of β₂-agonists decreases over time, for included studies that reported on exercise tests at various times after the administration of the β₂-agonist, we chose the shortest reported time after β₂-agonist administration. Of the 44 studies we included in our analysis, 39 (87%) published data of exercise test that was carried out within 1 hour after drug administration, and the others were carried out within 3 hours, except Carlsen (1995) which reported only the 10-12 hour exercise test.

As an example of misleading data extraction by Bonini [11], Kemp (1994) compared salbutamol and salmeterol in three exercise tests that were carried out 0.5, 5.5, and 11.5 hours after the administration of the β₂-agonist. In each time point, the FEV₁ decline was smaller after salmeterol than after salbutamol: 5% vs. 7% declines in the 0.5 hour test, 8% vs. 25% in the 5.5 hour test, and 13% vs. 27% in the 11.5 hour test, respectively. This means that at each time point salmeterol had a greater effect than salbutamol. However, in their Appendix 3, Bonini extracted the salbutamol FEV₁ decline from the 0.5 hour test (i.e. 7% FEV₁ decline) but the salmeterol FEV₁ decline from the 11.5 hour test (i.e. 13% FEV₁ decline) and thereby gives a biased impression that salbutamol was better than salmeterol because a smaller FEV₁ decline occurred after salbutamol. Such different time points were selected also for many other β₂-agonist comparisons, see below. Such arbitrary selection of exercise test times biases the presentation and analysis in the Bonini review.

The percentage decline in FEV₁ values in Table S3 indicate the change that occurred in the exercise test. The changes are negative, but the minus sign is not included.

For the references to the studies and to a description of the studies, see Bonini [11]:
https://doi.org/10.1002/14651858.CD003564.pub3
https://www.ncbi.nlm.nih.gov/pubmed/24089311
Table S4: Data extraction inconsistencies and errors in Bonini et al. (2013)

| Study             | Original report Source in the report | Bonini et al. [10] stated Appendix 3: Raw data for the maximal percent fall in FEV$_1$ calculations |
|-------------------|--------------------------------------|----------------------------------------------------------------------------------------------------|
| Blake (1999)      | FEV$_1$ decline: 5.36% (Salmeterol 25) [1 hr test] 5.64% (Salmeterol 50) [1 hr test] 13.5% (Placebo) [1 hr test] Table 3: 1 hour exercise test | FEV$_1$ decline: 7.99% (Salm 25) [6 hr test] 7.34% (Salm 50) [6 hr test] 14.0% (Placebo) [12 hr test] Given that the effect of β$_2$-agonists decreases over time, we used the 1 hour exercise tests. Furthermore, Bonini used different exercise test data for placebo and salmeterol. Furthermore, for salbutamol (Albuterol) and its placebo, Bonini gives the 1 hour exercise test results (3.8% and 13.5%, respectively). The same exercise test time should be used in the comparisons of the placebo and the β$_2$-agonists. |
| Bronsky (1995)    | FEV$_1$ decline: 6% (Albuterol Aerosol) 6% (Albuterol Powder) Table 1 | FEV$_1$ decline: 16.0% (Salb MDI) 26.0% (Salb Pwd) 10% and 20% have been added in error by Bonini to the published results. |
| Bronsky (1999)    | FEV$_1$ decline: 1.4% (Salmeterol Diskus) [1 hr] 0% (Salmeterol Diskhaler) [1 hr] 10.5% (Placebo) [1 hr] Fig 1 and text p. 503: 1 hr exercise test | FEV$_1$ decline: 5.6% (Salm Disk) [12 hr test] 5.7% (Salm Diskhal) [6 hr test] 12.1% (Placebo) [12 hr test] Given that the effect of β$_2$-agonists decreases over time, we used the 1 hour exercise tests. |
| Bronsky (2002)    | FEV$_1$ decline: ~6% (Formoterol 12 μg) [15 min] ~6% (Formoterol 24 μg) [15 min] Fig 1: 15 min after dosing | FEV$_1$ decline: 17.0% (Form 12 μg) [12 hr test] 14.6% (Form 24 μg) [12 hr test] Given that the effect of β$_2$-agonists decreases over time, we used the 15 min tests. |
| Daugbjerg (1996)  | FEV$_1$ decline: 9% (Formoterol) [3 hr test] Page 685 bottom. 3 hour exercise test. This 9% is reported as “median” in the original report. | FEV$_1$ decline: 11% (Form 12) [12 hr test] Given that the effect of β$_2$-agonists decreases over time, we used the 3 hour test. |
| Study            | Original report Source in the report                                                                                                                                                                                                 | Bonini et al. [10] stated Appendix 3: Raw data for the maximal percent fall in FEV\(_1\) calculations                                                                                                                                                                                                                     |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| De Benedictis (1996) | FEV\(_1\) decline: 10% (Salmeterol 25) [1 hr test] 4% (Salmeterol 50) [1 hr test] Table 2: 1 hour exercise test                                                                                                                                                                                                                                                                          | FEV\(_1\) decline: 19.0% (Salm 25) [12 hr test] 15.0% (Salm 50) [12 hr test] 35.0% (Placebo) [1 hr test] Given that the effect of \(\beta_2\)-agonists decreases over time, we used the 1 hour tests. The 1 hour test indicates substantially greater efficacy of salmeterol since the FEV\(_1\) declines are much smaller. Furthermore, Bonini used different exercise test data for placebo and salmeterol. The same exercise test time should be used in the comparison of placebo and \(\beta_2\)-agonist. |
| Del Col (1993)    | FEV\(_1\) decline: 0.76% (Albuterol + Jet) 2.37% (Albuterol + MDI) Table 3                                                                                                                                                                                                                                                                                    | FEV\(_1\) decline: 20.76% (Salb Jet) 12.37% (Salb MDI) 20% and 10% have been added in error by Bonini to the published results.                                                                                                                                                                                                         |
| Green (1992)     | FEV\(_1\) decline: 2.7% (Salmeterol) [1 hr test] Table 1: 1 hour exercise test.                                                                                                                                                                                                                                                                                    | FEV\(_1\) decline: 3.2% (Salm 50) [9 hr test] Given that the effect of \(\beta_2\)-agonists decreases over time, we used the 1 hour exercise test, though the difference is not great in this case. Furthermore, the exact FEV\(_1\) decline in the 9 hr test reported by Green (1992) was 3.4% and not the 3.2% stated by Bonini.                                          |
| Grönneröd (2000) | FEV\(_1\) decline: 5.40% (Formoterol 4.5 μg) [15 min] 2.50% (Formoterol 9 μg) [15 min] 18.4% (Placebo) [15 min test] Table 2: 15 min exercise test                                                                                                                                                                                                 | FEV\(_1\) decline: 9.2% (Form 4.5) [12 hr test] 5.4% (Form 9) [12 hr test] 18.4% (Placebo) [15 min test] Given that the effect of \(\beta_2\)-agonists decreases over time, we used the 15 min tests. For placebo, Bonini gives the FEV\(_1\) decline in the 15 min exercise test, but for formoterol results, Bonini seems to give the FEV\(_1\) decline in the 12 hour exercise tests (9.29% and 5.43%) rounded down. |
| Kemp (1994)      | FEV\(_1\) decline:                                                                                                                                                                                                                                                                                | FEV\(_1\) decline:                                                                                                                                                                                                                                                                                                             |
### Study | Original report Source in the report | Bonini et al. [10] stated Appendix 3: Raw data for the maximal percent fall in FEV\(_1\) calculations
--- | --- | ---
| | | Given that the effect of β\(_2\)-agonists decreases over time, we used the 0.5 hr tests.
| | | For the parallel test on salbutamol (Albuterol), Bonini gives the FEV\(_1\) decline in the 0.5 hour exercise test, but the salmeterol FEV\(_1\) decline is from the 11.5 hour exercise test.
| | | In the 0.5 hour test of salmeterol, the FEV\(_1\) decline is 5%, which is smaller than the decline in the 0.5 hour test of salbutamol (i.e. 7%), see left-hand side.
| | | Bonini’s selection of the 0.5 hour exercise test for salbutamol and the 11.5 hour test for salmeterol misleads readers since the FEV\(_1\) decline is greater on salmeterol treatment indicating that salmeterol is less effective. However, on each of the three reported time points, salmeterol was more effective in preventing FEV\(_1\) decline.

**König (1981)** | FEV\(_1\) decline for Study 1 is reported in Table 1 of König (1981) | Bonini does not include Study 1 results. Study 1 had 24 participants; of these 24 participants, 17 participated in study 2, for which Bonini gives the results. Study 1 had 10 min delay between inhaled metaproterenol and the exercise test. Study 2 had 1 hr delay between inhaled metaproterenol and the exercise test. Bonini writes as if there was a single trial which used two exercise tests “Time of exercise challenge after drug administration: 10 min, 1 hour” whereas König carried out two separate studies which used 10 min and 1 hour delay before the exercise tests.

**McAlpine (1990)** | FEV\(_1\) decline: 14.1% (Salbutamol) [2 hr test] Table 1: 2 hour exercise test | For the other studies, Bonini gives the results for all published β\(_2\)-agonists. For the McAlpine (1990) study, Bonini gives the formoterol results, but not the salbutamol results published in the same table.

**Newnham (1993)** | FEV\(_1\) decline: ~1% (Salmeterol) [1 hr test] 27.1% (Placebo) [1 hr test] Fig 1 and text p. 441 | FEV\(_1\) decline: 12.8% (Salmeterol) [12 hr test] 32.0% (Placebo) [6 hr test] Given that the effect of β\(_2\)-agonists decreases over time, we used the 1 hour tests. Furthermore, Bonini used different exercise test data for placebo and salmeterol.

**Pearlman (2006)** | FEV\(_1\) decline: 2.61% (Formoterol 12 μg) [15 min] | FEV\(_1\) decline: 7.6% (Form 12) [12 hr test]
| Study          | Original report Source in the report | Bonini et al. [10] stated Appendix 3: Raw data for the maximal percent fall in FEV\(_1\) calculations |
|---------------|-------------------------------------|------------------------------------------------------------------------------------------------------|
|               | 1.02\% (Formoterol 24 μg) [15 min]  | 5.9\% (Form 24) [12 hr test]  
|               | 11.11\% (Placebo) [15 min test]    | 13.2\% (Placebo) [4 hr test]  
|               | Table 3: 15 min exercise test       | Given that the effect of β\(_2\)-agonists decreases over time, we used the 15 min tests. 
|               |                                     | Furthermore, Bonini used different exercise test data for placebo and formoterol. The same exercise test time should be used in the comparison of the placebo and the β\(_2\)-agonists. |
| Philip (2007) | FEV\(_1\) decline:  
|               | 10.2\% (Salmeterol) [2 hr test]    | FEV\(_1\) decline:  
|               | Table 2: 2 hour exercise test       | 10.7\% (Salm 50) [8.5 hr test]  
|               |                                     | 21.8\% (Placebo) [2 hr test]  
|               |                                     | Given that the effect of β\(_2\)-agonists decreases in time, we used the 2 hour tests. 
|               |                                     | Furthermore, Bonini used different exercise test data for placebo and salmeterol. |
| Richter (2002)| FEV\(_1\) decline:  
|               | 6.3\% (Terbutaline) [30 min test]  | FEV\(_1\) decline:  
|               | 22.4\% (Placebo) [30 min test]     | 8.50\% (Terb 500) [60 min test]  
|               | Table 3: 30 min exercise test       | 25.1\% (Placebo) [60 min test]  
|               |                                     | For the parallel tests on formoterol and salmeterol, Bonini gives the FEV\(_1\) declined in the 30 min exercise tests (5.7% and 7.6%, respectively), but for the terbutaline and placebo FEV\(_1\) declines they give the results from the 60 min exercise test. 
|               |                                     | The same time exercise test should be used in the comparison of placebo and β\(_2\)-agonist. |
| Shapiro GS    | FEV\(_1\) decline:  
| (2002)        | 4.0\% (Formoterol 12 μg) [15 min]  | FEV\(_1\) decline:  
|               | 6.0\% (Formoterol 24 μg) [15 min]  | 12.4\% (Form 12) [12 hr test]  
|               | Table II: 15 min exercise test      | 17.5\% (Form 24) [12 hr test]  
|               |                                     | 10.0\% (Salb 180) [15 min test]  
|               |                                     | Given that the effect of β\(_2\)-agonists decreases over time, we used the 15 min tests. 
|               |                                     | For salbutamol, Bonini gives the FEV\(_1\) decline in the 15 min exercise test. Thereby the comparison with formoterol (i.e. 12 hr test) is biased and gives an impression that salbutamol is better, though formoterol is better in both the 15 min and the 12 hr tests when compared with salbutamol at the same time points. 
|               |                                     | The same time exercise test should be used in the comparison of placebo and β\(_2\)-agonists. 
|               |                                     | Finally, Bonini’s reference is erroneous, to a paper by a different Shapiro GG (1990): https://www.ncbi.nlm.nih.gov/pubmed/2145791 
|               |                                     | and not to the Shapiro GS (2002) though Bonini’s data are from the 2002 paper: https://www.ncbi.nlm.nih.gov/pubmed/12581546 |
Printouts of statistical calculations

Table 2 and Fig 2 calculations

```r
> BetaLmerI <- lmer(Beta$Difference ~ 1 + (1|Beta$Type:Beta$Study))
> summary(BetaLmerI)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta$Difference ~ 1 + (1 | Beta$Type:Beta$Study)

Random effects:
  Groups Name Variance Std.Dev.
  Beta$Type:Beta$Study (Intercept) 83.2     9.12
  Residual                     333.4    18.26
Number of obs: 187, groups: Beta$Type:Beta$Study, 14

Fixed effects:
  Estimate Std. Error t value
(Intercept)     27.7    2.8    9.91

> confint(BetaLmerI)
Computing profile confidence intervals ... 
  2.5 % 97.5 %
.sig01       5.1007 14.493
.sigma      16.4920 20.364
(Intercept) 22.0950 33.436

> BetaLmer <- lmer(Beta$Difference ~ Beta$Placebo + (Beta$Placebo|
  Beta$Type:Beta$Study))
> summary(BetaLmer)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta$Difference ~ Beta$Placebo + (Beta$Placebo | Beta$Type:Beta$Study)

Random effects:
  Groups Name Variance Std.Dev. Corr
  Beta$Type:Beta$Study (Intercept)  60.0372  7.748
  Beta$Placebo         0.0895  0.299  0.50
  Residual                          200.8788 14.173
Number of obs: 187, groups: Beta$Type:Beta$Study, 14

Fixed effects:
  Estimate Std. Error t value
(Intercept)     7.907    3.080    2.57
Beta$Placebo   -0.691    0.106  -6.54

Correlation of Fixed Effects:
  (Intr)
Beta$Placebo 0.663

> confint(BetaLmer)
Computing profile confidence intervals ... 
  2.5 %   97.5 %
.sig01        0.459740 14.40500
.sig02       -1.000000  0.68553
.sig03       -0.094367  0.51754
.sigma       12.759799 15.85445
(Intercept)   -1.850442 14.49775
Beta$Placebo -0.909915 -0.47769

There were 50 or more warnings (use warnings() to see the first 50)

> BetaLmerS <- lmer(Beta$Difference ~ Beta$Placebo -1+ (Beta$Placebo -1|
  Beta$Type:Beta$Study))
> summary(BetaLmerS)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta$Difference ~ Beta$Placebo - 1 + (Beta$Placebo - 1 | Beta$Type:Beta$Study)
```
REML criterion at convergence: 1570.8

Scaled residuals:
  Min  1Q Median  3Q  Max
-3.464 -0.227  0.135  0.511  4.545

Random effects:
  Groups     Name       Variance  Std.Dev.
Beta$Type:Beta$Study Beta$Placebo   0.0916   0.303
  Residual                          223.2708 14.942
Number of obs: 187, groups: Beta$Type:Beta$Study, 14

Fixed effects:
  Estimate  Std. Error t value
  Beta$Placebo -0.8975  0.0898  -10

> confint(BetaLmerS)
Computing profile confidence intervals ...  
   2.5 %   97.5 %
.sig01        0.18082  0.47730
.sigma       13.49674 16.67375
Beta$Placebo -1.08562 -0.71924

> anova(BetaLmerI, BetaLmer)
refitting model(s) with ML (instead of REML)
Data: NULL
Models:
  BetaLmerI: Beta$Difference ~ 1 + (1 | Beta$Type:Beta$Study)
  BetaLmer: Beta$Difference ~ Beta$Placebo + (Beta$Placebo | Beta$Type:Beta$Study)

   Df  AIC  BIC logLik deviance Chisq Chi Df Pr(>Chisq)
BetaLmerI  3 1642 1652   -818     1636
BetaLmer   6 1566 1585   -777     1554

82.3      3     <2e-16
***

---

> anova(BetaLmerS, BetaLmer)
refitting model(s) with ML (instead of REML)
Data: NULL
Models:
  BetaLmerS: Beta$Difference ~ Beta$Placebo - 1 + (Beta$Placebo - 1 | Beta$Type:Beta$Study)
  BetaLmer: Beta$Difference ~ Beta$Placebo + (Beta$Placebo | Beta$Type:Beta$Study)

   Df  AIC  BIC logLik deviance Chisq Chi Df Pr(>Chisq)
BetaLmerS  3 1574 1583   -784     1568
BetaLmer   6 1566 1585   -777     1554

13.9      3      0.003
**

---

> AIC(BetaLmerI, BetaLmerS)

   df   AIC
BetaLmerI  3 1638.3
BetaLmerS  3 1576.8

> median(abs(residuals(BetaLmerI)))
[1] 10.829
> median(abs(residuals(BetaLmerS)))
[1] 5.8229
Table 3 calculations

> Beta$Pl_10 <- Beta$Placebo<= -10&Beta$Placebo> -20
> Beta10 <- Beta[Beta$Pl_10 ==1,]
> Beta_10 <- lmer(Beta10$Difference ~ 1 + (1|Beta10$Type:Beta10$Study))
> summary(Beta_10)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta10$Difference ~ 1 + (1 | Beta10$Type:Beta10$Study)
REML criterion at convergence: 235.3

Random effects:
Groups Name Variance Std.Dev.
Beta10$Type:Beta10$Study (Intercept) 45.71 6.761
Residual 57.05 7.553
Number of obs: 33, groups: Beta10$Type:Beta10$Study, 12

Fixed effects:
Estimate Std. Error t value
(Intercept) 15.224 2.465 6.176

> confint(Beta_10)
Computing profile confidence intervals ...
2.5 % 97.5 %
.sig01 2.236469 11.92368
.sigma 5.749707 10.45168
(Intercept) 10.225639 20.29275
>
> length(Beta10$Placebo)
[1] 33
> mean(Beta10$Placebo)
[1] -15.49694
> sd(Beta10$Placebo)
[1] 2.674083
> mean(Beta10$Difference)
[1] 15.32273
> sd(Beta10$Difference)
[1] 10.00691
>

> Beta$Pl_20 <- Beta$Placebo<= -20&Beta$Placebo> -30
> Beta20 <- Beta[Beta$Pl_20 ==1,]
> Beta_20 <- lmer(Beta20$Difference ~ 1 + (1|Beta20$Type:Beta20$Study))
> summary(Beta_20)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta20$Difference ~ 1 + (1 | Beta20$Type:Beta20$Study)
REML criterion at convergence: 225.5

Random effects:
Groups Name Variance Std.Dev.
Beta20$Type:Beta20$Study (Intercept) 45.41 6.739
Residual 129.74 11.390
Number of obs: 29, groups: Beta20$Type:Beta20$Study, 12

Fixed effects:
Estimate Std. Error t value
(Intercept) 23.620 2.947 8.015

> confint(Beta_20)
Computing profile confidence intervals ...
2.5 % 97.5 %
.sig01 0.000000 12.95123
.sigma 8.547118 15.90304
(Intercept) 17.766230 29.86248
>
> length(Beta20$Placebo)
[1] 29

18
```r
> mean(Beta20$Placebo)
[1] -24.67914
> sd(Beta20$Placebo)
[1] 2.985238
> mean(Beta20$Difference)
[1] 22.59383
> sd(Beta20$Difference)
[1] 13.31154
>
> Beta$Pl_30 <- Beta$Placebo<= -30&Beta$Placebo> -40
> Beta30 <- Beta[Beta$Pl_30 ==1,]
> Beta_30 <- lmer(Beta30$Difference ~ 1 + (1|Beta30$Type:Beta30$Study))
> summary(Beta_30)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta30$Difference ~ 1 + (1 | Beta30$Type:Beta30$Study)
REML criterion at convergence: 290
Random effects:
 Groups     Name        Variance Std.Dev.
Beta30$Type:Beta30$Study (Intercept) 69.2  8.319
Residual                     293.1 17.119
Number of obs: 34, groups: Beta30$Type:Beta30$Study, 12
Fixed effects:
             Estimate Std. Error t value
(Intercept)  32.981     3.884   8.491
>
> confint(Beta_30)
Computing profile confidence intervals ... 
 2.5 %   97.5 %
.sig01  0.00000  17.71278
.sigma 13.10969 23.43105
(Intercept) 25.03157 40.92001
>
> length(Beta30$Placebo)
[1] 34
> mean(Beta30$Placebo)
[1] -34.54618
> sd(Beta30$Placebo)
[1] 2.646329
> mean(Beta30$Difference)
[1] 32.81453
> sd(Beta30$Difference)
[1] 18.87488
>
> Beta$Pl_40 <- Beta$Placebo<= -40&Beta$Placebo> -50
> Beta40 <- Beta[Beta$Pl_40 ==1,]
> Beta_40 <- lmer(Beta40$Difference ~ 1 + (1|Beta40$Type:Beta40$Study))
> summary(Beta_40)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta40$Difference ~ 1 + (1 | Beta40$Type:Beta40$Study)
REML criterion at convergence: 242.1
Random effects:
 Groups     Name        Variance Std.Dev.
Beta40$Type:Beta40$Study (Intercept) 125.6 11.21
Residual                     218.7 14.79
Number of obs: 29, groups: Beta40$Type:Beta40$Study, 11
Fixed effects:
             Estimate Std. Error t value
(Intercept)  39.703     4.572   8.683
>
> confint(Beta_40)
```

19
Computing profile confidence intervals ...
   2.5 %  97.5 %
.sig01   2.822957 20.31467
.sigma   11.159536 20.52371
(Intercept) 30.588948 49.30061
>
> length(Beta40$Placebo)
[1] 29
> mean(Beta40$Placebo)
[1] -44.47872
> sd(Beta40$Placebo)
[1] 3.108381
> mean(Beta40$Difference)
[1] 36.85131
> sd(Beta40$Difference)
[1] 18.82314
>
>
> Beta$Pl_50 <- Beta$Placebo <= -50
> Beta50 <- Beta[Beta$Pl_50 == 1,]
> Beta_50 <- lmer(Beta50$Difference ~ 1 + (1|Beta50$Type:Beta50$Study))
> summary(Beta_50)
Linear mixed model fit by REML ['lmerMod']
Formula: Beta50$Difference ~ 1 + (1 | Beta50$Type:Beta50$Study)

REML criterion at convergence: 294.6

Random effects:
 Groups            Name   Variance Std.Dev.  
Beta50$Type:Beta50$Study (Intercept) 104.0 10.20  
Residual                        332.8 18.24  
Number of obs: 34, groups: Beta50$Type:Beta50$Study, 10

Fixed effects:
(Intercept)   44.302 4.775  9.278

> confint(Beta_50)
Computing profile confidence intervals ...
   2.5 %  97.5 %
.sig01  0.000000 20.76483
.sigma 14.16507 24.91224
(Intercept) 34.82413 54.63546
>
>
> length(Beta50$Placebo)
[1] 34
> mean(Beta50$Placebo)
[1] -59.85812
> sd(Beta50$Placebo)
[1] 7.317866
> mean(Beta50$Difference)
[1] 42.50647
> sd(Beta50$Difference)
[1] 20.43452
Fig 3 calculations

```r
> BetaOver10 <- Beta[Beta$Placebo<=-10,]
> skewness(BetaOver10$Relative)
[1] 1.053634
>
> iqr=c(0.25, 0.5, 0.75)
> BetaQR <- rq(Beta$Difference ~ Beta$Placebo -1, tau = iqr)
> summary(BetaQR)

Call: rq(formula = Beta$Difference ~ Beta$Placebo - 1, tau = iqr)

tau: [1] 0.25

Coefficients:
Beta$Placebo
-0.6

Call: rq(formula = Beta$Difference ~ Beta$Placebo - 1, tau = iqr)

tau: [1] 0.5

Coefficients:
Beta$Placebo
-0.88462

Call: rq(formula = Beta$Difference ~ Beta$Placebo - 1, tau = iqr)

tau: [1] 0.75

Coefficients:
Beta$Placebo
-1.03129
```
> MeansLmerI <- lmer(Means$Difference ~ 1 + (1|Means$Type), weights = Means$N)
> summary(MeansLmerI)
Linear mixed model fit by REML ['lmerMod']
Formula: Means$Difference ~ 1 + (1 | Means$Type)
Weights: Means$N

Random effects:
  Groups     Name        Variance Std.Dev.
     Means$Type (Intercept)  5.28   2.3
     Residual               1341.48 36.6
Number of obs: 44, groups: Means$Type, 9

Fixed effects:
            Estimate Std. Error t value
(Intercept)  21.42      1.76   12.2

> MeansLmer <- lmer(Means$Difference ~ Means$Placebo + (Means$Placebo|
     Means$Type), weights = Means$N)

Warning message:
In checkConv(attr(opt, "derivs"), opt$par, ctrl = control$checkConv,  :
  Model failed to converge with max|grad| = 0.00455223 (tol = 0.002, component 1)
> summary(MeansLmer)
Linear mixed model fit by REML ['lmerMod']
Formula: Means$Difference ~ Means$Placebo + (Means$Placebo | Means$Type)
Weights: Means$N

Random effects:
  Groups     Name          Variance Std.Dev. Corr
     Means$Type Means$Placebo    0      0.0
     Residual                 1021.172 31.956
Number of obs: 44, groups: Means$Type, 9

Fixed effects:
            Estimate Std. Error t value
(Intercept)  16.426    6.970      2.36
Means$Placebo  -0.241    0.210    -1.15

Correlation of Fixed Effects:
  (Intr)
Means$Placb 0.975
Model failed to converge with max|grad| = 0.00455223 (tol = 0.002, component 1)

> MeansLmerS <- lmer(Means$Difference ~ Means$Placebo -1 + (Means$Placebo-1|
     Means$Type), weights = Means$N)
> summary(MeansLmerS)
Linear mixed model fit by REML ['lmerMod']
Formula: Means$Difference ~ Means$Placebo - 1 + (Means$Placebo - 1 | Means$Type)
Weights: Means$N

Random effects:
  Groups     Name    Variance Std.Dev.
     Means$Type Means$Placebo    0      0.0
     Residual                1489.038 38.6
Number of obs: 44, groups: Means$Type, 9

Fixed effects:
            Estimate Std. Error t value
 22
Means$Placebo  -0.7662  0.0504  -15.2

> anova(MeansLmer,MeansLmerI)
refitting model(s) with ML (instead of REML)
Data: NULL
Models:
MeansLmerI: Means$Difference ~ 1 + (1 | Means$Type)
MeansLmer: Means$Difference ~ Means$Placebo + (Means$Placebo | Means$Type)

Df  AIC   BIC logLik deviance Chisq Chi Df Pr(>Chisq)
MeansLmerI 3 326 331  -160      320
MeansLmer  6 323 334  -156      311
          8.52      3      0.0366 *
---

> anova(MeansLmer,MeansLmerS)
refitting model(s) with ML (instead of REML)
Data: NULL
Models:
MeansLmerS: Means$Difference ~ Means$Placebo - 1 + (Means$Placebo - 1 | Means$Type)
MeansLmer: Means$Difference ~ Means$Placebo + (Means$Placebo | Means$Type)

Df  AIC   BIC logLik deviance Chisq Chi Df Pr(>Chisq)
MeansLmerS 3 329 334  -161      323
MeansLmer  6 323 334  -156      311
          11.3      3      0.01  *
---

> AIC(MeansLmerI,MeansLmerS)
df    AIC
MeansLmerI 3 323.49
MeansLmerS 3 332.96
Fig 5: Calculation of slope and its SE for each of the 14 studies with IPD

```r
> And <- Beta[Beta$Study=="Anderson2001",]
> summary(AndLm <- lm(And$Difference ~ And$Placebo - 1 ))

Call:
  lm(formula = And$Difference ~ And$Placebo - 1 )

Coefficients:        Estimate Std. Error t value Pr(>|t|)
  And$Placebo -0.70931    0.04783 -14.83 3.37e-14 ***
---

Residual standard error: 10.69 on 26 degrees of freedom
Multiple R-squared:  0.8943,  Adjusted R-squared:  0.8902
F-statistic: 219.9 on 1 and 26 DF,  p-value: 3.37e-14

> mean(And$bAgon)
[1]  -10.96852
> sd(And$bAgon)
[1]  12.31758

> mean(And$Placebo)
[1]  -39.4037
> sd(And$Placebo)
[1]  17.57891

> Bon <- Beta[Beta$Study=="Boner1994",]
> summary(lm(Bon$Difference ~ Bon$Placebo - 1 ))

Call:
  lm(formula = Bon$Difference ~ Bon$Placebo - 1 )

Coefficients:           Estimate Std. Error t value Pr(>|t|)
  Bon$Placebo -0.4562     0.1970  -2.316   0.0362 *
---

Residual standard error: 14.81 on 14 degrees of freedom
Multiple R-squared:  0.277,  Adjusted R-squared:  0.2253
F-statistic: 5.363 on 1 and 14 DF,  p-value: 0.03624

> mean(Bon$bAgon)
[1]  -9.533333
> sd(Bon$bAgon)
[1]  15.53276

> mean(Bon$Placebo)
[1]  -14.46667
> sd(Bon$Placebo)
[1]  13.39438
```

24
Deb <- Beta[Beta$Study=="Debelic1988",]
summary(lm(Deb$Difference ~ Deb$Placebo - 1))

Call:
  lm(formula = Deb$Difference ~ Deb$Placebo - 1)

Coefficients:
  Estimate Std. Error t value  Pr(>|t|)
Deb$Placebo  -0.6289     0.1465 -4.294 0.000639 ***

---

Residual standard error: 25.51 on 15 degrees of freedom  
Multiple R-squared:  0.5514,  Adjusted R-squared:  0.5215 
F-statistic: 18.44 on 1 and 15 DF,  p-value: 0.0006393

mean(Deb$bAgon)
[1] -12.6125
sd(Deb$bAgon)
[1] 27.55965
mean(Deb$Placebo)
[1] -38.54375
sd(Deb$Placebo)
[1] 20.92268

de96 <- Beta[Beta$Study=="de Benedictis 1996",]
summary(lm(de96$Difference ~ de96$Placebo - 1))

Call:
  lm(formula = de96$Difference ~ de96$Placebo - 1)

Coefficients:
  Estimate Std. Error t value  Pr(>|t|)
de96$Placebo  -0.90246    0.02504 -36.05 9.02e-13 ***

---

Residual standard error: 3.408 on 11 degrees of freedom 
Multiple R-squared:  0.9916,  Adjusted R-squared:  0.9908 
F-statistic:  1299 on 1 and 11 DF,  p-value: 9.02e-13

mean(de96$bAgon)
[1] -4
sd(de96$bAgon)
[1] 3.190896
mean(de96$Placebo)
[1] -36.33333
sd(de96$Placebo)
[1] 15.62244


> de98 <- Beta[Beta$Study=="de Benedictis 1998",]
> summary(lm(de98$Difference ~ de98$Placebo - 1))

Call:
  lm(formula = de98$Difference ~ de98$Placebo - 1)

Coefficients:
            Estimate Std. Error t value Pr(>|t|)
de98$Placebo  -0.90489    0.04605 -19.65 6.46e-10 ***

---

Residual standard error: 5.022 on 11 degrees of freedom
Multiple R-squared:  0.9723, Adjusted R-squared:  0.9698
F-statistic: 386.1 on 1 and 11 DF,  p-value: 6.464e-10

> mean(de98$bAgon)
[1] -3.75
> sd(de98$bAgon)
[1] 4.433857
> mean(de98$Placebo)
[1] -25.75
> sd(de98$Placebo)
[1] 18.91188

> Din <- Beta[Beta$Study=="Dinh Xuan 1989",]
> summary(lm(Din$Difference ~ Din$Placebo - 1))

Call:
  lm(formula = Din$Difference ~ Din$Placebo - 1)

Coefficients:
            Estimate Std. Error t value Pr(>|t|)
Din$Placebo  -0.94646    0.07758 -12.2   6.69e-07 ***

---

Residual standard error: 10.96 on 9 degrees of freedom
Multiple R-squared:  0.943, Adjusted R-squared:  0.9366
F-statistic: 148.8 on 1 and 9 DF,  p-value: 6.688e-07

> mean(Din$bAgon)
[1] 0.0509
> sd(Din$bAgon)
[1] 11.25025
> mean(Din$Placebo)
[1] -41.0796
> sd(Din$Placebo)
[1] 18.55219
>
```r
> Gre <- Beta[Beta$Study=="Green1992",]
> summary(lm(Gre$Difference ~ Gre$Placebo - 1 ))

Call:
  lm(formula = Gre$Difference ~ Gre$Placebo - 1)

Coefficients:
   Estimate Std. Error t value Pr(>|t|)
Gre$Placebo  -1.588      0.127 -12.5 3.06e-08 ***

---

Residual standard error: 11.65 on 12 degrees of freedom
Multiple R-squared:  0.9287,  Adjusted R-squared:  0.9228
F-statistic: 156.3 on 1 and 12 DF,  p-value: 3.057e-08

> mean(Gre$bAgon)
[1] 14.35285
> sd(Gre$bAgon)
[1] 12.46346
> mean(Gre$Placebo)
[1] -21.17462
> sd(Gre$Placebo)
[1] 14.69036

> He83 <- Beta[Beta$Study=="Henriksen1983",]
> summary(lm(He83$Difference ~ He83$Placebo - 1 ))

Call:
  lm(formula = He83$Difference ~ He83$Placebo - 1)

Coefficients:
   Estimate Std. Error t value Pr(>|t|)
He83$Placebo  -0.29063    0.08418 -3.452  0.00429 **

---

Residual standard error: 15.3 on 13 degrees of freedom
Multiple R-squared:  0.4783,  Adjusted R-squared:  0.4382
F-statistic: 11.92 on 1 and 13 DF,  p-value: 0.004289

> mean(He83$bAgon)
[1] -30.50721
> sd(He83$bAgon)
[1] 22.57338
> mean(He83$Placebo)
[1] -46.29679
> sd(He83$Placebo)
[1] 15.20486
```
> He92 <- Beta[Beta$Study=="Henriksen1992",]
> summary(lm(He92$Difference ~ He92$Placebo - 1 ))

Call: lm(formula = He92$Difference ~ He92$Placebo - 1 )

Coefficients: Estimate Std. Error t value Pr(>|t|)
He92$Placebo -0.9344 0.1522 -6.141 7.3e-05 ***
---
Residual standard error: 24.16 on 11 degrees of freedom
Multiple R-squared: 0.7742, Adjusted R-squared: 0.7536
F-statistic: 37.71 on 1 and 11 DF, p-value: 7.303e-05

> mean(He92$bAgon)
[1] -1.165583
> sd(He92$bAgon)
[1] 24.33675
> mean(He92$Placebo)
[1] -43.75
> sd(He92$Placebo)
[1] 14.29638

> Pea <- Beta[Beta$Study=="Pearlman2007",]
> summary(lm(Pea$Difference ~ Pea$Placebo - 1 ))

Call: lm(formula = Pea$Difference ~ Pea$Placebo - 1 )

Coefficients: Estimate Std. Error t value Pr(>|t|)
Pea$Placebo -0.9665 0.0231 -41.75 4.29e-16 ***
---
Residual standard error: 2.304 on 14 degrees of freedom
Multiple R-squared: 0.992, Adjusted R-squared: 0.9915
F-statistic: 1743 on 1 and 14 DF, p-value: 4.287e-16

> mean(Pea$bAgon)
[1] -1.306667
> sd(Pea$bAgon)
[1] 2.06725
> mean(Pea$Placebo)
[1] -21.76
> sd(Pea$Placebo)
[1] 14.15197

>
Rob <- Beta[Beta$Study=="Robertson1994",]
summary(lm(Rob$Difference ~ Rob$Placebo- 1 ))

Call:
  lm(formula = Rob$Difference ~ Rob$Placebo - 1)

Coefficients:
            Estimate Std. Error t value Pr(>|t|)
Rob$Placebo  -1.5855     0.4845  -3.273   0.0136 *
---
Residual standard error: 16.47 on 7 degrees of freedom
Multiple R-squared: 0.6048, Adjusted R-squared: 0.5483
F-statistic: 10.71 on 1 and 7 DF, p-value: 0.01362

> mean(Rob$bAgon)
[1] 12.0215
> sd(Rob$bAgon)
[1] 12.75419
> mean(Rob$Placebo)
[1] -8.32975
> sd(Rob$Placebo)
[1] 9.262858

Sch <- Beta[Beta$Study=="Schoeffel1981",]
summary(lm(Sch$Difference ~ Sch$Placebo - 1 ))

Call:
  lm(formula = Sch$Difference ~ Sch$Placebo - 1)

Coefficients:
             Estimate Std. Error t value Pr(>|t|)
Sch$Placebo  -0.8397     0.0437 -19.21 1.29e-08 ***
---
Residual standard error: 5.438 on 9 degrees of freedom
Multiple R-squared: 0.9762, Adjusted R-squared: 0.9736
F-statistic: 369.2 on 1 and 9 DF, p-value: 1.293e-08

> mean(Sch$bAgon)
[1] -5.58
> sd(Sch$bAgon)
[1] 6.261842
> mean(Sch$Placebo)
[1] -37.56
> sd(Sch$Placebo)
[1] 12.36916
Sim <- Beta[Beta$Study=="Simons1997",]
summary(lm(Sim$Difference ~ Sim$Placebo - 1))

Call:
  lm(formula = Sim$Difference ~ Sim$Placebo - 1)

Coefficients:
            Estimate Std. Error t value Pr(>|t|)
Sim$Placebo -1.29220  0.06678 -19.35 2.96e-09 ***
---

Residual standard error: 5.758 on 10 degrees of freedom
Multiple R-squared:  0.974,  Adjusted R-squared:  0.9714
F-statistic: 374.5 on 1 and 10 DF,  p-value: 2.961e-09

mean(Sim$bAgon)
[1] 7.942636
sd(Sim$bAgon)
[1] 5.218767
mean(Sim$Placebo)
[1] -23.62709
sd(Sim$Placebo)
[1] 11.37575

Wal <- Beta[Beta$Study=="Walker1986",]
summary(lm(Wal$Difference ~ Wal$Placebo - 1))

Call:
  lm(formula = Wal$Difference ~ Wal$Placebo - 1)

Coefficients:
            Estimate Std. Error  t value Pr(>|t|)
Wal$Placebo  -1.0832     0.2387  -4.537  0.000848 ***
---

Residual standard error: 26.13 on 11 degrees of freedom
Multiple R-squared:  0.6518,  Adjusted R-squared:  0.6201
F-statistic: 20.59 on 1 and 11 DF,  p-value: 0.0008476

mean(Wal$bAgon)
[1] 11.14825
sd(Wal$bAgon)
[1] 23.55104
mean(Wal$Placebo)
[1] -26.16592
sd(Wal$Placebo)
[1] 18.4925
Estimation of the possible role of the regression to the mean phenomenon

Approach 1

```r
> str(Placebo)
'data.frame': 45 obs. of 4 variables:
$ Study     : Factor w/ 4 levels "deBenedictis1996",...
$ Placebo1  : num 35 48 30 35 19 61 19 60 27 54...
$ Placebo2  : num 26 46 8 29 23 50 25 50 23 48...

> Placebo$Difference <- Placebo$Placebo2 - Placebo$Placebo1
>
> PlaceboLmer <- lmer(Placebo$Difference ~ Placebo$Placebo1 + (Placebo$Placebo1 | Placebo$Study))
> summary(PlaceboLmer)
```

Linear mixed model fit by REML ['lmerMod']

```
Formula: Placebo$Difference ~ Placebo$Placebo1 + (Placebo$Placebo1 | Placebo$Study)

Random effects:
  Groups        Name             Variance     Std.Dev.     Corr
  Placebo$Study (Intercept) 2.517846e-06 1.586772e-03
  Placebo$Placebo1 6.591825e-09 8.119005e-05 -1.00000
  Residual                       7.007141e+01 8.370866e+00

Number of obs: 45, groups: Placebo$Study, 4

Fixed effects:    Estimate Std. Error t value
  (Intercept) 1.61510507 2.95396576  0.54676
Placebo$Placebo1 -0.15287875 0.08054546 -1.89804

Correlation of Fixed Effects:
  (Intr) Placebo$Plcb1 -0.906
```
Approach 2

```r
> str(PlaceboLm)
'data.frame': 103 obs. of 3 variables:
$ Study : Factor w/ 4 levels "de Benedictis 1996",..: 1 1 1 1 1 1 1 1 1 1 ... $ person: Factor w/ 45 levels "1","2","3","4",...: 1 2 3 4 5 6 7 8 9 10 ... $ FEV1 : num 35 48 30 35 19 61 19 60 27 54 ...

Plac_Var4 <- lmer(PlaceboLm$FEV1 ~ 1 + (1|PlaceboLm$person))

Plac_Var4
Linear mixed model fit by REML ['lmerMod']
Formula: PlaceboLm$FEV1 ~ 1 + (1 | PlaceboLm$person)
REML criterion at convergence: 778.1398
Random effects:
Groups Name Std.Dev. 
PlaceboLm$person (Intercept) 14.02300
Residual 6.23319 # SD based on mixed-effects model
Number of obs: 103, groups: PlaceboLm$person, 45
Fixed Effects:
(Intercept) 31.77804

> # Blomqvist formula calculation
> sd(Beta$Placebo)
[1] 18.878
> rho <- 1 - (6.23319^2/18.87793^2)
> rho
[1] 0.89098
> beta_observed <- -0.6911
> beta_true <- (beta_observed + 1 - rho)/rho
> beta_true
[1] -0.6533
> ratio_beta <- beta_true/beta_observed
> ratio_beta
[1] 0.94531
Only about 5% error due to regression to mean, which is small compared with the width of the 95% CI of the slope

# Placebo-test vs placebo test
> beta_observed <- -0.15288
> beta_true <- (beta_observed + 1 - rho)/rho
> beta_true # essentially all slope is due to regression to mean
[1] -0.049225
```